Naploy NPLY
Naploy Q3 FY26: revenue $5K, up 202%; diluted EPS $0.00
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001683168-26-004218
Key figures from this report
These are the numbers Naploy reported for Q3 FY26, the quarter ended Apr 30, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$5K+202% from $2K in Q3 FY2510-Q income statement, on EDGAR
- Net income−$476Against −$4K in Q3 FY2510-Q income statement, on EDGAR
- Diluted EPS$0.00Against $0.00 in Q3 FY2510-Q income statement, on EDGAR
- Cash and cash equivalents$16K+52% from $10K in Q3 FY2510-Q balance sheet, on EDGAR
- Cash from operations$9KAgainst −$17K in Q3 FY2510-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 8000 and related industry codes: the same peer list as the financial tables.
- Alps Group ALPS
- American Oncology Network AONC
- Agape ATP ATPC public float $5M, Dec 31, 2025
- Anew Health AVG
- Better Therapeutics BTTX
